During the past decade, Michigan State University Center for Bleeding and Clotting Disorders conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Michigan State University Center for Bleeding and Clotting Disorders" #1 collaborator was "American Thrombosis and Hemostasis Network" with 1 trials as a collaborator, "Atlantic Research Group" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Bioverativ Therapeutics Inc." with 1 trials as a collaborator and "CSL Behring" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Michigan State University Center for Bleeding and Clotting Disorders" are "Hemophilia A" (2 trials), "Hemophilia A With Inhibitor" (2 trials), "Factor VII Deficiency" (1 trials), "Glanzmann Thrombasthenia" (1 trials) and "Haemophilia A Without Inhibitor" (1 trials). Many other conditions were trialed in "Michigan State University Center for Bleeding and Clotting Disorders" in a lesser frequency.

Most popular intervention types in "Michigan State University Center for Bleeding and Clotting Disorders" are "Biological" (3 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Coagulation Factor VIIa variant" (1 trials), "Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013" (1 trials), "Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013" (1 trials), "GreenGene™ F" (1 trials) and "GreenGene™ F and an approved recombinant Factor VIII product" (1 trials). Other intervention names were less common.

The vast majority of trials in "Michigan State University Center for Bleeding and Clotting Disorders" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Michigan State University Center for Bleeding and Clotting Disorders". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Michigan State University Center for Bleeding and Clotting Disorders, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Michigan State University Center for Bleeding and Clotting Disorders, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".